Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
76-90 of 4420 results
Johnson & Johnson to buy Actelion for $30bn
By PBR Staff Writer
US healthcare giant Johnson & Johnson (J&J) has agreed to acquire Swiss biopharmaceutical firm Actelion for $30bn.
Drug Research > Drug Discovery & Development > News
Connect secures $25m financing to advance immune modulators clinical development
Connect Biopharmaceuticals has completed a $20m Series A financing to advance clinical development of novel immune modulators.
Drug Research > Drug Discovery & Development > News
Discuva secures Innovate UK grant for new antibiotics development
Innovate UK has awarded a £1.5m Biomedical Catalyst early-stage award to drug discovery firm Discuva for the development of novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections.
Drug Research > Drug Discovery & Development > News
Cue Biopharma raises $26M in funding
Cue Biopharma has announced a total of $26m of invested private capital, led by MDB Capital Group, to develop next-generation biologics to selectively control T Cell activity.
Drug Research > Drug Discovery & Development > News
ELC Group partners with PSR Group for advanced drug development
Global life sciences partner ELC Group is collaborating with New Zealand-based research and development firm Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.
Drug Research > Drug Discovery & Development > News
Merck, Domain Therapeutics partner to co-develop adenosine receptor antagonists
Merck has entered into a collaboration and licensing agreement with French based Domain Therapeutics to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
Drug Research > Drug Discovery & Development > News
Cytori to buy Azaya’s nanoparticle Development Platform
By PBR Staff Writer
Cytori Therapeutics has agreed to acquire certain assets from oncology firm Azaya Therapeutics in a deal potentially worth $170m.
Drug Research > Drug Discovery & Development > News
Ethypharm agrees to acquire UK-based Martindale Pharma
Ethypharm has agreed to acquire Martindale Pharma, a UK-based specialty pharmaceutical firm offering essential medicines to more than 50 countries across the world.
Drug Research > Drug Discovery & Development > News
Takeda, Ovid to co-develop rare pediatric epilepsy candidate TAK-935
Takeda Pharmaceutical said its rare pediatric epilepsy candidate TAK-935 will be co-developed through a partnership with Ovid Therapeutics.
Drug Research > Drug Discovery & Development > News
Horizon Discovery broadens gene editing capabilities
Horizon Discovery Group has expanded its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR edited cell lines for the Good Manufacturing Practice (GMP) manufacturing of biotherapeutics.
Drug Research > Drug Discovery & Development > News
Malin buys 33% interest in UK's Wren Therapeutics
By PBR Staff Writer
Irish life sciences firm Malin has acquired a 33% stake in UK biopharmaceutical company, Wren Therapeutics.
Drug Research > Drug Discovery & Development > News
Aptevo Therapeutics receives $20m payment from Emergent BioSolutions
Aptevo Therapeutics has received a $20m cash payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent, effective August 1, 2016.
Drug Research > Drug Discovery & Development > News
Nivalis Therapeutics unveils corporate restructuring
Nivalis Therapeutics, a clinical stage pharmaceutical firm engaged in the development of new solutions for people with cystic fibrosis (CF), announced that its board of directors has approved a restructuring plan as part of its initiative to evaluate strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources.
Drug Research > Drug Discovery & Development > News
Clinical-stage biopharmaceutical firm OncoImmune raises $15m funding
OncoImmune, a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases, has secured $15m in Series A round of fundraising led by 3E Bioventures Capital.
Drug Research > Drug Discovery & Development > News
Merck expands oncology portfolio with four Vertex cancer programs
By PBR Staff Writer
Merck has agreed to license four oncology research and development (R&D) programs from Vertex Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
76-90 of 4420 results